Published in Biotech Business Week, January 29th, 2007
Terms of the acquisition were not disclosed.
"Combining the resources of these two organizations demonstrates Boston Scientific's commitment to leadership in treating carotid artery disease," said John Pedersen, president of Boston Scientific's Peripheral Interventions business. "Incorporating the NexStent Carotid Stent into our portfolio...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.